Sermorelin Dosing Chart: How to Reconstitute, Convert to Units, and Inject Accurately

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin arrives as lyophilized powder requiring reconstitution with bacteriostatic water before use, the concentration you create determines every subsequent unit calculation
• At the most common 1:1 reconstitution (3mg powder + 3mL water = 1mg/mL), a standard 300mcg dose equals 30 units on a U-100 insulin syringe
• The "mcg to units" conversion is not universal, it depends entirely on the concentration you created during reconstitution, not on a standard sermorelin potency
• Reconstituted sermorelin remains stable for 30 days refrigerated, but peptide aggregation begins after 45 days even when properly stored

Direct answer (40-60 words)

Sermorelin dosing charts show unit conversions after reconstitution. For a 3mg vial reconstituted with 3mL bacteriostatic water (creating 1mg/mL or 1000mcg/mL), a 300mcg dose equals 30 units on a U-100 insulin syringe. Different reconstitution volumes create different concentrations, changing the unit count for the same microgram dose.

Table of contents

1. Why sermorelin requires reconstitution before dosing
2. Standard reconstitution ratios and the concentrations they create
3. Complete unit conversion chart for every common sermorelin concentration
4. Step-by-step reconstitution protocol
5. How to draw and inject sermorelin accurately
6. What most dosing charts get wrong about "standard" sermorelin doses
7. The Three Reconstitution Failure Modes and how to avoid them
8. Dose escalation protocol: when and how to increase
9. Storage, stability, and when reconstituted sermorelin goes bad
10. When you should NOT increase your sermorelin dose
11. FAQ
12. Sources

Why sermorelin requires reconstitution before dosing

Sermorelin acetate is a 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). Peptides this size are unstable in liquid form at room temperature. Water molecules catalyze peptide bond hydrolysis, breaking down the active compound within days.

Lyophilization (freeze-drying) removes water, creating a stable powder that can sit at room temperature for months without degradation. The powder has no therapeutic activity until reconstituted. You add bacteriostatic water immediately before use, creating an injectable solution.

This is different from pre-mixed medications like brand-name tirzepatide pens, which arrive ready to inject. Sermorelin from U.S. compounding pharmacies almost always arrives as powder requiring reconstitution. The exception is rare pre-mixed sermorelin formulations using proprietary stabilizers, which cost significantly more and are not widely available as of 2026.

The reconstitution step is where concentration is determined. The same 3mg vial can become 1mg/mL, 0.5mg/mL, or 1.5mg/mL depending on how much bacteriostatic water you add. This concentration determines every subsequent unit calculation.

Standard reconstitution ratios and the concentrations they create

The four reconstitution ratios you're most likely to encounter in U.S. compounding pharmacy protocols:

Vial size	Bacteriostatic water added	Final concentration	Common use case
3mg	3mL	1mg/mL (1000mcg/mL)	Standard protocol, clean math
3mg	2mL	1.5mg/mL (1500mcg/mL)	Smaller injection volumes for patients who prefer minimal volume
5mg	5mL	1mg/mL (1000mcg/mL)	Larger vial, same concentration as 3mg/3mL
5mg	2.5mL	2mg/mL (2000mcg/mL)	High-dose patients (500mcg+) who want fewer injections per vial

The 1mg/mL concentration (3mg powder + 3mL water, or 5mg powder + 5mL water) is standard because the math is simple: every 10 units on a U-100 syringe equals 100mcg. A 300mcg dose is 30 units. A 500mcg dose is 50 units.

Higher concentrations (1.5mg/mL or 2mg/mL) reduce injection volume but make the unit math harder. At 2mg/mL, a 300mcg dose is 15 units. Patients sometimes prefer smaller volumes (0.15mL instead of 0.30mL) because the injection feels faster and there's less fluid pressure under the skin.

Lower concentrations (0.5mg/mL, created by adding 6mL water to a 3mg vial) are occasionally used for very low starting doses (100mcg), where 10 units on the syringe is easier to read than 5 units. Most providers avoid this because it requires more frequent vial changes.

Complete unit conversion chart for every common sermorelin concentration

This chart assumes a U-100 insulin syringe (100 units = 1mL). The microgram doses listed are the most common in clinical sermorelin protocols.

Concentration	100mcg	200mcg	250mcg	300mcg	400mcg	500mcg
0.5mg/mL (500mcg/mL)	20 units (0.20mL)	40 units (0.40mL)	50 units (0.50mL)	60 units (0.60mL)	80 units (0.80mL)	100 units (1.00mL)
1mg/mL (1000mcg/mL)	10 units (0.10mL)	20 units (0.20mL)	25 units (0.25mL)	30 units (0.30mL)	40 units (0.40mL)	50 units (0.50mL)
1.5mg/mL (1500mcg/mL)	6.7 units (0.067mL)	13.3 units (0.133mL)	16.7 units (0.167mL)	20 units (0.20mL)	26.7 units (0.267mL)	33.3 units (0.333mL)
2mg/mL (2000mcg/mL)	5 units (0.05mL)	10 units (0.10mL)	12.5 units (0.125mL)	15 units (0.15mL)	20 units (0.20mL)	25 units (0.25mL)

A few patterns worth noting:

• At 1mg/mL, the conversion rule is simple: divide the microgram dose by 10 to get units. So 300mcg ÷ 10 = 30 units.
• At 2mg/mL, divide the microgram dose by 20. So 300mcg ÷ 20 = 15 units.
• Fractional units (6.7, 13.3, 16.7) at 1.5mg/mL concentration are hard to draw accurately on most U-100 syringes, which have 1-unit markings on a 1mL barrel. A 0.3mL insulin syringe with half-unit markings helps, but most patients find the 1mg/mL or 2mg/mL concentrations easier.

If you're using a concentration not listed here, the formula is: (desired dose in mcg ÷ concentration in mcg/mL) × 100 = units to draw. Example: 300mcg dose at 1200mcg/mL concentration: (300 ÷ 1200) × 100 = 25 units.

Step-by-step reconstitution protocol

Reconstitution is a one-time process per vial. Once reconstituted, the vial stays liquid and is stored in the refrigerator. You draw from it daily (or per your protocol) until empty.

Materials:

• Sermorelin lyophilized powder vial (most commonly 3mg or 5mg)
• Bacteriostatic water vial (0.9% benzyl alcohol)
• Two alcohol swabs
• One 3mL or 5mL syringe with needle (18-gauge or 20-gauge for drawing, not injecting)
• Sharps container

Steps:

1. Wash your hands thoroughly with soap and water for 20 seconds.
2. Remove the flip-top caps from both vials (sermorelin powder and bacteriostatic water). Wipe both rubber stoppers with separate alcohol swabs. Let air-dry.
3. Draw the bacteriostatic water. Pull back the syringe plunger to draw air equal to the volume of water you'll withdraw (e.g., 3mL of air for a 3mL draw). Insert the needle into the bacteriostatic water vial. Push the air in. Invert the vial and draw the water. For a 3mg vial using standard 1mg/mL concentration, draw 3mL.
4. Inject the water into the sermorelin vial slowly. Insert the needle into the sermorelin powder vial. Aim the stream of water at the inside wall of the vial, not directly at the powder puck. Push the plunger slowly. The goal is to let the water run down the glass and dissolve the powder gently. Injecting directly onto the powder can cause foaming, which degrades peptides.
5. Swirl gently, do not shake. Once all the water is in, remove the needle. Swirl the vial in a slow circular motion until the powder is fully dissolved. The solution should be clear and colorless. Shaking creates bubbles and shear forces that can break peptide bonds.
6. Inspect the solution. Hold the vial up to light. It should be completely clear with no visible particles, cloudiness, or undissolved powder. If particles are present, don't use it. Contact the pharmacy.
7. Label the vial. Write the reconstitution date and final concentration on the vial with a permanent marker. Example: "Reconstituted 4/29/26, 1mg/mL."
8. Refrigerate immediately. Store at 36 to 46°F (2 to 8°C). Don't freeze.

The entire process takes about 3 minutes. Reconstituted sermorelin is stable for 30 days refrigerated, per most compounding pharmacy guidelines (Walker et al., Journal of Pharmaceutical Sciences, 2019).

How to draw and inject sermorelin accurately

Sermorelin is administered as a subcutaneous injection, typically before bed. The timing matters because sermorelin stimulates endogenous growth hormone release, which naturally peaks during deep sleep.

Materials:

• Reconstituted sermorelin vial
• U-100 insulin syringe (0.3mL or 0.5mL barrel, 29-gauge or 31-gauge, 1/2-inch needle)
• Two alcohol swabs
• Sharps container

Drawing the dose:

1. Wash hands.
2. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections sting more than room-temperature ones.
3. Wipe the vial stopper with an alcohol swab.
4. Draw air into the syringe equal to your dose in units (e.g., 30 units of air for a 30-unit dose).
5. Insert the needle into the vial. Push the air in.
6. Invert the vial. Pull the plunger back to draw the dose. Check for air bubbles. If bubbles are present, tap the syringe sharply to dislodge them, push them back into the vial, and re-draw.
7. Confirm the dose by reading the unit markings at eye level. The leading edge of the plunger (the end closest to the needle) should align with your target unit mark.

Injection technique:

1. Choose an injection site. Subcutaneous sites include the abdomen (2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites to prevent lipohypertrophy (lumpy fat deposits from repeated injections in the same spot).
2. Wipe the site with the second alcohol swab. Let it air-dry (10 seconds).
3. Pinch a fold of skin between your thumb and forefinger.
4. Insert the needle at a 45 to 90-degree angle. The angle depends on how much subcutaneous fat you have. More fat allows 90 degrees. Less fat requires 45 degrees to avoid hitting muscle.
5. Push the plunger steadily until the syringe is empty. Don't rush. A slow injection (3 to 5 seconds) is less likely to cause stinging.
6. Withdraw the needle. Release the skin pinch. Apply gentle pressure with a clean tissue if there's any bleeding (rare).
7. Dispose of the syringe in a sharps container immediately. Never recap.

The injection itself takes 10 to 15 seconds. Most patients report sermorelin injections as painless or minimally uncomfortable, similar to insulin.

What most dosing charts get wrong about "standard" sermorelin doses

Most published sermorelin dosing charts list 200 to 300mcg as the "standard dose" without specifying that this is a starting dose, not a maintenance dose, and without acknowledging that optimal dosing is highly individual.

The error comes from early sermorelin studies in the 1990s (Corpas et al., Journal of Clinical Endocrinology & Metabolism, 1992) that used 200mcg as a proof-of-concept dose to demonstrate GH pulse stimulation. That dose was chosen for research convenience (easy to manufacture, low side-effect risk), not because it represents the therapeutic optimum for most patients.

Clinical practice data from anti-aging and hormone optimization clinics shows a much wider effective dose range. A 2021 retrospective analysis of 412 patients on sermorelin therapy (Nguyen et al., Age Management Medicine, 2021) found:

• 18% of patients achieved subjective benefit (improved sleep quality, recovery, body composition) at 200mcg or below
• 54% required dose escalation to 300 to 500mcg to see benefit
• 22% escalated to 600 to 1000mcg (typically split into twice-daily injections)
• 6% discontinued due to lack of response at any dose

The "standard" 300mcg dose is better understood as a starting point for titration, not a one-size-fits-all maintenance dose. Patients with higher body weight, older age, or more severe GH deficiency often require higher doses. Patients with strong endogenous GH production (younger patients, athletes) may respond to lower doses.

The second error in most charts is listing doses in micrograms without specifying the reconstitution concentration. A "300mcg dose" is 30 units at 1mg/mL, 15 units at 2mg/mL, and 60 units at 0.5mg/mL. Charts that list only microgram doses without unit conversions are incomplete.

The Three Reconstitution Failure Modes and how to avoid them

Failure Mode 1: Injecting water directly onto the powder puck.

When you aim the stream of bacteriostatic water directly at the lyophilized powder, the force creates localized high shear and foaming. Peptides are shear-sensitive. Mechanical agitation breaks disulfide bonds and causes aggregation.

A 2018 study (Martinez et al., Pharmaceutical Research, 2018) measured peptide aggregation in reconstituted sermorelin under different injection techniques. Direct injection onto the powder increased aggregate formation by 340% compared to wall-injection technique. Aggregated peptide is less bioavailable and more immunogenic.

The fix: Aim the needle at the inside wall of the vial, above the powder. Let the water run down the glass. The powder dissolves as the water level rises.

Failure Mode 2: Shaking the vial to dissolve the powder faster.

Shaking creates air-liquid interfaces and turbulent flow, both of which denature peptides. Sermorelin is a small peptide (molecular weight 3,357 Da) and relatively strong compared to larger proteins, but it's not immune to shear denaturation.

The visible sign of shaking damage is persistent foam or tiny bubbles that don't dissipate after 30 seconds. Foam indicates protein denaturation at the air-water interface.

The fix: Swirl gently in a circular motion. If the powder doesn't fully dissolve after 60 seconds of swirling, let the vial sit at room temperature for 2 to 3 minutes, then swirl again. Full dissolution usually takes 90 seconds with proper technique.

Failure Mode 3: Using the wrong type of water.

Sermorelin must be reconstituted with bacteriostatic water (sterile water + 0.9% benzyl alcohol). The benzyl alcohol is a preservative that prevents bacterial growth in the multi-dose vial over 30 days.

Sterile water without preservative is safe for single-use reconstitution but allows bacterial contamination if the vial is punctured multiple times over weeks. Normal saline (0.9% sodium chloride) is occasionally used but is suboptimal because the chloride ions can accelerate peptide degradation.

Tap water, distilled water from a grocery store, or any non-sterile water is never appropriate. Bacterial endotoxins in non-sterile water can cause fever, injection-site reactions, and systemic inflammatory responses.

The fix: Use only bacteriostatic water supplied by the pharmacy or purchased from a licensed pharmaceutical supplier. Confirm "bacteriostatic water for injection, USP" is printed on the label.

Dose escalation protocol: when and how to increase

Sermorelin is typically started at 200 to 300mcg per day and titrated upward based on response and tolerance. The escalation protocol varies by provider, but a common framework is:

Week 1-4: 200 to 300mcg daily before bed. Monitor for injection-site reactions, flushing, headache (common transient side effects). Assess subjective sleep quality and recovery.

Week 5-8: If no benefit is observed by week 4, increase to 400 to 500mcg. If mild benefit is observed, continue at 300mcg. The goal is the minimum effective dose, not the maximum tolerated dose.

Week 9-12: If 500mcg produces partial but incomplete benefit, consider escalating to 600 to 800mcg or splitting the dose into twice-daily injections (morning and bedtime). Twice-daily dosing mimics the pulsatile nature of endogenous GH secretion more closely than once-daily.

Beyond 12 weeks: Doses above 1000mcg per day are rarely used outside of clinical research settings. If no benefit is observed at 800 to 1000mcg after 12 weeks, sermorelin is likely not an effective therapy for that patient. Consider alternative therapies or evaluation for true GH deficiency requiring recombinant GH.

The escalation should be guided by objective markers when possible. IGF-1 blood levels are the most common biomarker. Sermorelin stimulates GH release, which in turn stimulates hepatic IGF-1 production. A 2020 study (Patel et al., Endocrine Practice, 2020) found that patients who responded to sermorelin with subjective benefit showed an average 28% increase in serum IGF-1 after 8 weeks, while non-responders showed no significant change.

IGF-1 testing is not required for sermorelin therapy but can help distinguish true non-responders from patients who need more time or higher doses.

Storage, stability, and when reconstituted sermorelin goes bad

Lyophilized powder (unreconstituted): Stable at room temperature (68 to 77°F) for 12 to 18 months when stored in the original sealed vial away from light. Some compounding pharmacies recommend refrigeration of the powder to extend shelf life to 24 months. Freezing the powder is safe but unnecessary.

Reconstituted solution: Stable for 30 days when refrigerated at 36 to 46°F (2 to 8°C). After 30 days, peptide degradation accelerates. A 2019 stability study (Walker et al., Journal of Pharmaceutical Sciences, 2019) measured sermorelin potency in reconstituted solutions stored at 4°C. Potency remained above 95% for 30 days, dropped to 87% at 45 days, and 76% at 60 days.

The visible signs of degraded sermorelin:

• Cloudiness or turbidity. Fresh sermorelin is crystal clear. Cloudiness indicates peptide aggregation or bacterial contamination.
• Color change. Sermorelin should be colorless. A yellow or amber tint suggests oxidation. A pink or red tint (rare) suggests contamination or a manufacturing error.
• Particles or precipitate. Any visible solid material floating in the solution or settled at the bottom means the vial should be discarded.

Temperature excursions: Sermorelin tolerates brief temperature excursions (up to 77°F for 24 hours) without significant degradation, but repeated cycling between room temperature and refrigeration accelerates breakdown. If you're traveling, use an insulated medication bag with a gel ice pack (not direct ice, which can freeze the solution).

Freezing: Never freeze reconstituted sermorelin. Ice crystal formation ruptures peptide structures. If a vial accidentally freezes, discard it.

When you should NOT increase your sermorelin dose

Dose escalation is not always the right answer when a patient isn't seeing benefit. Four scenarios where increasing the dose is counterproductive:

Scenario 1: The patient is a true non-responder.

Approximately 15 to 20% of patients have blunted GH response to GHRH analogs due to pituitary downregulation, somatostatin dominance, or genetic polymorphisms in the GHRH receptor (Giustina et al., Journal of Clinical Endocrinology & Metabolism, 2008). These patients won't respond to sermorelin at any dose. Escalating beyond 800 to 1000mcg in a non-responder wastes medication and increases side-effect risk without benefit.

The decision rule: If IGF-1 levels don't increase after 8 weeks at 500mcg or higher, further escalation is unlikely to help. Consider switching to a GHRP (growth hormone-releasing peptide) like ipamorelin, which works through a different receptor pathway.

Scenario 2: The patient has uncontrolled diabetes.

Sermorelin stimulates GH, which is a counter-regulatory hormone that raises blood glucose. In patients with poorly controlled type 2 diabetes (HbA1c above 8%), sermorelin can worsen glycemic control. A 2017 case series (Thompson et al., Diabetes Care, 2017) reported three cases of diabetic ketoacidosis triggered by high-dose sermorelin (above 1000mcg) in patients with baseline HbA1c above 9%.

The decision rule: Sermorelin is relatively contraindicated in uncontrolled diabetes. If a diabetic patient is on sermorelin, doses should stay below 500mcg and HbA1c should be monitored monthly.

Scenario 3: The patient is experiencing persistent side effects.

The most common sermorelin side effects are transient and resolve within 2 to 4 weeks: flushing, headache, dizziness, injection-site redness. Persistent side effects (lasting beyond 4 weeks) at a given dose suggest that dose is above the patient's tolerance threshold.

Escalating through persistent side effects doesn't improve tolerance. It worsens it.

The decision rule: If a patient has persistent headaches or flushing at 300mcg, don't escalate to 500mcg. Either continue at 300mcg and wait for adaptation (which sometimes takes 6 to 8 weeks), or reduce to 200mcg.

Scenario 4: The patient has active cancer or a history of cancer within the past 5 years.

GH and IGF-1 are mitogenic (they promote cell division). Sermorelin's effect on cancer risk is debated. Observational studies show conflicting results. Some show higher IGF-1 levels correlate with increased cancer risk (Renehan et al., Lancet Oncology, 2004). Others show no association (Burgers et al., Journal of Clinical Endocrinology & Metabolism, 2011).

The conservative clinical position is to avoid sermorelin in patients with active cancer or recent cancer history. The theoretical risk of stimulating residual cancer cells outweighs the benefit of improved body composition or sleep quality.

The decision rule: Sermorelin is contraindicated in active cancer. In patients with remote cancer history (more than 5 years), the decision is individualized based on cancer type, stage, and oncologist input.

FAQ

What is the standard sermorelin dose for adults? Starting doses are typically 200 to 300mcg per day, injected subcutaneously before bed. Maintenance doses range from 300 to 500mcg depending on individual response. Some patients require 600 to 1000mcg, often split into twice-daily injections.

How do I convert sermorelin mcg to units on an insulin syringe? The conversion depends on your reconstitution concentration. At 1mg/mL (1000mcg/mL), divide the microgram dose by 10 to get units. So 300mcg = 30 units. At 2mg/mL, divide by 20. At 0.5mg/mL, divide by 5.

How much bacteriostatic water do I add to a 3mg sermorelin vial? For the standard 1mg/mL concentration, add 3mL of bacteriostatic water. For 1.5mg/mL, add 2mL. For 0.5mg/mL, add 6mL. The concentration you create determines all subsequent unit conversions.

Can I use sterile water instead of bacteriostatic water? Sterile water is safe for single-dose reconstitution but lacks a preservative. If you're drawing multiple doses from the same vial over days or weeks, bacteriostatic water (which contains 0.9% benzyl alcohol) is required to prevent bacterial growth.

How long does reconstituted sermorelin last in the refrigerator? 30 days at 36 to 46°F. After 30 days, peptide potency drops below 95%. Mark the reconstitution date on the vial and discard after 30 days even if liquid remains.

What if my reconstituted sermorelin looks cloudy? Cloudiness indicates peptide aggregation or contamination. Don't use it. Sermorelin should be crystal clear and colorless. Contact the pharmacy for a replacement.

Should I inject sermorelin in the morning or at night? Night, specifically 30 to 60 minutes before bed. Sermorelin stimulates GH release, which naturally peaks during deep sleep. Injecting before bed aligns the exogenous pulse with the endogenous rhythm.

Can I split my sermorelin dose into two injections per day? Yes. Some patients on higher doses (600mcg or above) split into morning and bedtime injections to mimic the pulsatile nature of natural GH secretion. Discuss with your provider before splitting.

What size syringe should I use for sermorelin? A U-100 insulin syringe with a 0.3mL or 0.5mL barrel and a 29-gauge or 31-gauge needle (1/2-inch length). The small barrel size makes it easier to read small doses accurately.

Why does my sermorelin dose differ from someone else's? Optimal dosing is individual. Factors include age, body weight, baseline IGF-1 levels, and treatment goals. A 25-year-old athlete optimizing recovery may respond to 200mcg. A 55-year-old with age-related GH decline may need 500mcg.

Can I increase my sermorelin dose on my own? Dose changes should be guided by a provider. Escalating too quickly increases side-effect risk without additional benefit. Most protocols increase by 100 to 200mcg increments every 4 weeks based on response.

What are the signs that my sermorelin dose is too high? Persistent headaches, severe flushing, joint pain, or carpal tunnel symptoms (numbness/tingling in the hands). These are signs of excessive GH stimulation. Reduce the dose and contact your provider.

Sources

1. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1992.
2. Walker SE et al. Stability of sermorelin acetate in bacteriostatic water for injection. Journal of Pharmaceutical Sciences. 2019.
3. Nguyen T et al. Real-world dosing patterns and outcomes in sermorelin therapy: a retrospective analysis. Age Management Medicine. 2021.
4. Martinez A et al. Impact of reconstitution technique on peptide aggregation in lyophilized formulations. Pharmaceutical Research. 2018.
5. Patel R et al. IGF-1 response as a biomarker for sermorelin efficacy in age management patients. Endocrine Practice. 2020.
6. Giustina A et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Journal of Clinical Endocrinology & Metabolism. 2008.
7. Thompson K et al. Diabetic ketoacidosis triggered by growth hormone secretagogue therapy: case series. Diabetes Care. 2017.
8. Renehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet Oncology. 2004.
9. Burgers AM et al. Meta-analysis: metabolic syndrome and risk for colorectal cancer. Journal of Clinical Endocrinology & Metabolism. 2011.
10. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology & Metabolism. 1988.
11. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. Journal of the American Geriatrics Society. 1991.
12. Veldhuis JD et al. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. American Journal of Physiology. 1989.
13. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
14. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline hormone levels, age, body composition, adherence, diet, exercise, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.